（记者 曾健辉） 每经头条（nbdtoutiao）——重磅数据公布：回升！专访徐洪才："内卷式竞争"得到一定缓解，下一 步"补收入"可形成良性循环 每经AI快讯，汇宇制药1月21日晚间发布公告称，公司第二届第六次董事会会议于2026年1月21日在公 司会议室以通讯方式召开。会议审议了《关于预计公司2026年度日常性关联交易的议案》等文件。 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2026-004 四川汇宇制药股份有限公司 股东减持股份结果公告 本次减持计划实施前，四川汇宇制药股份有限公司(以下简称"公司")股 东王晓鹏女士持有公司股份数量为 17,037,557 股，占公司总股本的 4.022%； 上述股份来源于公司首次公开发行前取得的股份，且已于 2022 年 10 月 26 日起解除限售并上市流通。 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 减持计划的实施结果情况 2026 年 1 月 21 日，公司收到股东王晓鹏女士出具的《关于减持公司股份 结果的告知函》。截至 2026 年 1 月 21 日，股东王晓鹏通过集中竞价方式减 持公司股份数量 339,432 股，占公司总股本的比例为 0.080 %。本次减持计 划已实施完毕，实施结果情况如下： | 一、减持主体减持前基本情况 | | --- | | 股东名称 | 王晓鹏 | | | | --- | --- | --- | --- | | ...

证券代码：688553 证券简称：汇宇制药 公告编号：2026-003 四川汇宇制药股份有限公司 关于申请银行授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"或"汇宇制药"）于2026年1 月21日召开第二届董事会第二十二次会议，审议通过了《关于申请银行授信额度的 议案》，本次授信无需提交股东会审议。现将具体情况公告如下： 为满足公司生产经营和业务发展需要，公司及子公司拟以土地及房地产抵押、 信用方式向银行等金融机构申请总额不超过人民币11亿元的综合授信额度，授信产 品包括但不限于流动资金贷款、银行承兑汇票、保函、信用证、票据贴现等综合业 务，具体授信业务种类、额度、期限和利率，以各方实际签订的相关合同为准。 特此公告。 四川汇宇制药股份有限公司 董事会 2026 年 1 月 22 日 1 该综合授信事项有效期为自董事会审议通过之日起12个月，在授信期限内，授 信额度可循环使用，可以在不同银行间进行调整。 为了提高工作效率，公司董事会授权总经理或其指定的授权代理人在 ...

一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 证券代码：688553 证券简称：汇宇制药 公告编号：2026-002 四川汇宇制药股份有限公司 关于预计2026年度日常性关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：否。 日常关联交易对上市公司的影响：本次预计的关联交易基于四川汇宇 制药股份有限公司（以下简称"汇宇制药"或"公司"）及其子公司正常生产经 营需要，以日常生产经营业务为基础，以市场价格为定价依据，交易定价公允、 结算时间与方式合理，不影响公司的独立性，不存在损害公司及全体股东利益的 情形，不会对关联人形成较大的依赖。 公司于 2026 年 1 月 21 日就该议案组织召开了第二届独立董事专门会议第六 次会议进行审议，并获全体独立董事一致同意，认为公司 2026 年度日常关联交 易预计，为公司正常经营业务所需，属正常商业行为，严格遵守了平等、自愿、 等价、有偿的原则，交易定价公平合理，符合中国证监会、上海证券交易所和公 司关于关联交易管理的有 ...

表决结果：同意 3 票，反对 0 票，弃权 0 票。 四川汇宇制药股份有限公司 第二届董事会独立董事专门会议 第六次会议决议 四川汇宇制药股份有限公司（以下简称"公司"）第二届董事会独立董事专 门会议第六次会议于 2026 年 1 月 21 日在公司会议室以通讯方式召开，本次会议 通知及相关资料于 2026 年 1 月 16 日发出。本次会议由全体独立董事共同推举龙 永强先生担任会议召集人并主持本次会议，会议应出席独立董事 3 名，实际出席 独立董事 3 名。本次会议的召集、召开和表决程序符合《上市公司独立董事管理 办法》等法律、法规、规范性文件和《公司章程》的有关规定。 全体独立董事对本次会议议案进行了审议，以记名投票表决方式，通过如下 决议： 一、审议通过《关于预计公司 2026 年度日常性关联交易的议案》 经全体与会独立董事审议：公司 2026 年度日常关联交易预计，为公司正常 经营业务所需，属正常商业行为，严格遵守了平等、自愿、等价、有偿的原则， 交易定价公平合理，符合中国证监会、上海证券交易所和公司关于关联交易管理 的有关规定，不存在损害公司及其他股东特别是中小股东利益的情形，不会影响 公司的独立性 ...

南财智讯1月21日电，汇宇制药公告，公司股东王晓鹏通过集中竞价方式减持公司股份33.94万股，占公 司总股本的0.08%。本次减持价格区间为20.37元至21.08元/股，减持总金额为704.82万元。减持后，王 晓鹏持有公司股份16,698,125股，持股比例降至3.942%。本次减持计划已实施完毕，实际减持情况与此 前披露的计划一致。 ...

Core Viewpoint - The company, Huyou Pharmaceutical, has achieved significant milestones in its overseas market expansion, with 25 products approved for sale in 68 countries and regions by the mid-2025 report date [2]. Group 1: Overseas Market Expansion - As of the mid-2025 report date, the company has obtained approvals for 25 products in overseas markets [2]. - The company has established a presence in 68 countries and regions, indicating a broad international reach [2]. Group 2: Sales Strategy in Europe - The company's sales model in Europe primarily follows a self-operated approach, with seven subsidiaries established in key countries including the UK, Ireland, France, Germany, the Netherlands, Italy, and Portugal [2]. - A robust marketing system and extensive channel network have been developed to support sales in Europe [2]. - The company plans to accelerate the construction and depth of its direct sales network in Europe [2].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

Core Viewpoint - The announcement highlights the collaboration between the company's subsidiary, Huyou Haiyue, and AstraZeneca to conduct clinical trials for HYP-6589 in combination with Osimertinib for treating specific types of non-small cell lung cancer [1] Group 1: Company Developments - Huyou Haiyue has developed HYP-6589, a highly selective SOS1 small molecule inhibitor, which is currently in the clinical trial phase [1] - The collaboration with AstraZeneca involves a clinical trial agreement to study the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with Osimertinib [1] Group 2: Industry Context - Osimertinib, marketed as Tagrisso, is a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor developed by AstraZeneca, already approved in China for specific non-small cell lung cancer treatments [1] - The partnership aims to explore innovative treatment options in the oncology sector, particularly for non-small cell lung cancer, which remains a significant area of focus in cancer research [1]

Core Viewpoint - The announcement highlights a clinical trial collaboration between Huayu Pharmaceutical's subsidiary and AstraZeneca, focusing on the innovative drug HYP-6589, which is a selective SOS1 small molecule inhibitor [1] Group 1: Company Overview - Huayu Pharmaceutical's subsidiary, Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd., has signed a clinical trial cooperation agreement with AstraZeneca [1] - The innovative drug HYP-6589 (project code: HY-0006) is being developed by Huayu Pharmaceutical and is classified as a Class I innovative drug [1] Group 2: Drug Development and Collaboration - The collaboration aims to study the clinical combination of HYP-6589 and AstraZeneca's drug Osimertinib (brand name: Tagrisso), which is a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor approved for specific types of non-small cell lung cancer in China [1] - This partnership is expected to accelerate the clinical trial process for Huayu Pharmaceutical's innovative drug, enhance research and development efficiency, and expand the company's new drug development capabilities [1] - The collaboration may also help to save time and costs associated with clinical trials, ensuring the smooth progress of the project [1]